# atai Life Sciences N.V.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atai-life-sciences-n-v

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.atai.life
- Total disclosed funding: $328M
- Latest round: Series D (Mar 3, 2021)
- Investors on record: 17

## About

Founded in 2018 and based in Munich, Germany, atai Life Sciences N.V. operates as a biopharmaceutical company aiming to transform the treatment of mental health disorders. The company was co-founded by Founder Christian Angermayer, CEO Florian Brand, CSO Srinivas Rao, and Lars Christian Wilde. In March 2021, atai Life Sciences raised USD 157 million in Series D funding co-led by Apeiron Investment Group, Thiel Capital, Woodline Partners, and the company's founder Mr. Christian Angermayer. The company filed its IPO Filing in February 2021.

The company operates as a biopharmaceutical company that develops disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds. It is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. The company offers its business model that combines funding, technology, scientific and regulatory expertise that focuses on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential.

The company plans to expand and develop its drug candidate pipeline and enabling technologies, continue its current clinical developments, and hire teams in order to continue delivering key milestones. The company also plans to be listed on the Nasdaq under the symbol ATAI.

## Funding rounds

- Series D, Mar 3, 2021, $157M — Highline Capital Management, Alpha Wave Global, Pura Vida Investments, Infinitas Capital, Gaingels, Fearless Ventures, Subversive Capital, Apeiron Investment Group, Thiel Capital, Woodline Partners, What If Ventures, Catalio Capital Management, Korify Capital
- Series C, Nov 23, 2020, $125M — Alpha Wave Global, Pura Vida Investments, Apeiron Investment Group, Future Ventures, Galaxy Asset Management, Catalio Capital Management
- Series B, Mar 27, 2019, $43M — Apeiron Investment Group, Subversive Capital, Bail Capital
- Seed, Jun 7, 2018, $3.6M — Nimble Ventures

## Investors

- Nimble Ventures (https://capitalatlas.ai/funds/nimble-ventures) — Seed
- Apeiron Investment Group (https://capitalatlas.ai/funds/apeiron-investment-group) — Series B, Series C, Series D
- Subversive Capital (https://capitalatlas.ai/funds/subversive-capital) — Series B, Series D
- Bail Capital (https://capitalatlas.ai/funds/bail-capital) — Series B
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series C, Series D
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series C, Series D
- Future Ventures — Series C
- Galaxy Asset Management (https://capitalatlas.ai/funds/galaxy-asset-management) — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C, Series D
- Highline Capital Management — Series D
- Infinitas Capital — Series D
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series D
- Fearless Ventures (https://capitalatlas.ai/funds/fearless-ventures) — Series D
- Thiel Capital — Series D
- Woodline Partners — Series D
- What If Ventures (https://capitalatlas.ai/funds/what-if-ventures) — Series D
- Korify Capital (https://capitalatlas.ai/funds/korify-capital) — Series D